https://www.globenewswire.com/news-release/2023/10/10/2757329/0/en/Akero-Therapeutics-Reports-Encouraging-36-Week-Analysis-of-96-Week-Phase-2b-SYMMETRY-Study-with-a-Trend-on-Fibrosis-Improvement-and-Statistically-Significant-Results-for-NASH-Resol.html
0
0
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an - GlobeNewswire
+ 83 more
10/10/23 at 11:00am
Organization
GlobeNewswire
Author
Akero Therapeutics
Details
64 words
Summarize
Business & Industrial Health Conditions Akero Therapeutics Reports EFX Fibrosis Insulin Sensitization SYMMETRY Study NASH Resolution GLOBE NEWSWIRE
22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36,...
Create an account or login to join the discussion